This study is for patients with multiple myeloma. The purpose of the study is to learn more about investigational cells, called OriCAR-017 (the ‘study cells’), which are made from the participant’s own blood cells. This research will find out if the study cells can be given to people safely, identify the most appropriate dose for further research, and see if the study cells may be helpful for people with multiple myeloma that has come back after previous treatment (relapsed) or did not respond to previous treatment (refractory).

The purpose of the study is to learn more about an investigational product called LN-145 (the ‘study cells’) in participants with Non-Small Cell Lung Cancer (NSCLC). The study cells are immune cells that have identified cancer cells as abnormal and have penetrated into the tumor to try to kill cancer cells. These cells are called tumor-infiltrating lymphocytes, or TILs. Participants in this study will have tumor tissue collected during a biopsy or surgery, and the TILs will be isolated and grown in a lab. The TILs will then be given back to the participant. We are hoping to find out if the study cells can be given to participants safely, and if it helps them.

The purpose of this study is to see if investigational study cells, called CAR T cells, are safe and tolerable for participants with multiple myeloma that has returned after previous treatment (relapsed) or did not respond to previous treatment (refractory). The investigational study cells are made from participant's own immune cells (called T-cells) that are genetically modified by the study funder. The study will also see if the investigational CAR T cells kill tumor cells.